Photo courtesy of Yonhap News

 

 

[Alpha Biz= Ellie Kim] Daewoong Pharmaceutical announced on May 21 that it is advancing research and development of “reverse aging” therapies, aiming to restore aged cells to a more youthful state.

Unlike conventional anti-aging approaches that slow the aging process, reverse aging focuses on rejuvenating already aged cells. The company recently secured key technology assets and rights from U.S.-based Turn Biotechnologies through an auction process.

Turn Biotechnologies is known for its ERA (Epigenetic Reprogramming of Aging) platform, which utilizes messenger RNA (mRNA)-based partial reprogramming technology. This approach is designed to selectively restore cellular function while preserving the original identity of the cells.

Daewoong plans to collaborate with its affiliate HanAll Biopharma to expand research into age-related conditions, including ophthalmic and hearing disorders.

Interest in longevity and aging reversal technologies has been growing globally amid rapid population aging. High-profile investors such as Jeff Bezos and Peter Thiel have also backed startups focused on extending healthspan.

The move signals Daewoong’s entry into a next-generation biotech field that could reshape treatment approaches for age-related diseases.

 

 

[ⓒ 메디컬투데이. 무단전재-재배포 금지]